Clinical Trial

FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis

Study acronym: FARGO
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 29, 2026 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
FARGO is a randomised, phase IIa, multi-centre, placebo-controlled trial to compare Faecal Microbiota Transplant (FMT) with placebo in patients with primary sclerosing cholangitis (PSC) and concomitant inflammatory bowel disease.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-02-23; most recent amendment 2026-04-28.
Status change: Not Yet Recruiting → Recruiting 2024-05-14
Trial Details
NCT Number NCT06286709
Lead Sponsor University of Birmingham
Collaborators: PSC Support, Life Arc
Conditions Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases
Enrollment 58 participants
Start Date 2024-03-27
Primary Completion 2026-04-30 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-04-29